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Abstract  
Background. Simultaneous polydrug use (SPU) may represent a greater incremental risk factor 
for human health than concurrent polydrug use (CPU). However, few studies have examined 
these patterns of use in relation to health issues, particularly with regard to the number of drugs 
used. 
Methods. In the present study, we have analyzed data from a representative sample of 5,734 
young Swiss males from the Cohort Study on Substance Use Risk Factors. Exposure to drugs 
(i.e., alcohol, tobacco, cannabis, and 15 other illicit drugs) as well as mental, social, and physical 
factors were studied through regression analysis. 
Results. We found that individuals engaging in CPU and SPU followed the known stages of 
drug use, involving initial experiences with licit drugs (e.g., alcohol and tobacco) followed by 
use of cannabis and then other illicit drugs. In this regard, two classes of illicit drugs were 
identified, including first uppers, hallucinogens and sniffed drugs; and then ‘harder’ drugs 
(ketamine, heroin, and crystal meth), which were only consumed by polydrug users who were 
already taking numerous drugs. Also, we observed an association between the number of drugs 
used simultaneously and social issues (i.e., social consequences and aggressiveness). In fact, the 
more often the participants simultaneously used substances, the more likely they were to 
experience social problems. In contrast, we did not find any relationship between SPU and 
depression, anxiety, health consequences, or health. 
Conclusions. Here, we have identified some associations with SPU that are independent of CPU. 
Also, we found that the number of concurrently used drugs can be a strong factor associated with 
mental and physical health, and that their simultaneous use may not significantly contribute to 
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this association. Furthermore, the negative effects related to the use of one substance might be 
counteracted by the use of an additional substance. 
Keywords: concurrent polydrug use; drug use pattern; mental and physical health; number of 
drugs used; simultaneous polydrug use.
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 1. Introduction 
Substance use disorder represents the most prevalent form of psychopathology in young adults 
[1, 2]. Although it is well known that single drug use is rare [3-7], there have been few studies 
investigating polydrug use (i.e., the ingestion of more than one drug [3]). Indeed, polydrug use is 
associated with a unique set of consequences [8], including psychological morbidity/pathology 
[9-11], health risk behaviors [12] (e.g., HIV risk-taking [5]), difficulties engaging in drug-abuse 
therapy [13], and worse outcomes following drug-abuse treatment [14]. Moreover, some studies 
have indicated that the abuse of a higher number of substances is associated with more severe 
health outcomes [15-18]. 
 
Two forms of polydrug use have been described: concurrent and simultaneous [19]. Concurrent 
polydrug use (CPU) is the use of two or more substances within a given time period. On the 
other hand, simultaneous polydrug use (SPU) is the use of two or more substances at the same 
time, on a single occasion [20]. SPU is known to be a subset of CPU [21]. Furthermore, SPU is 
considered to be a key characteristic of the substance use patterns associated with many drug 
users, especially teenagers and young adults [1, 22-24], and studies have demonstrated that SPU 
poses a greater health risk than CPU [21]. For example, simultaneous polydrug users reported 
more drug use-related problems than concurrent polydrug users [21]. Also, those engaging in 
SPU displayed more social problems/consequences, psychosocial distress (e.g., depression) [19, 
20], anxiety [19], and health problems [19, 20, 25]. In addition, the risk of injury, poisoning, 
overdose [26] or suicide [25] was higher during SPU. Similarly, SPU led to an increased 
likelihood for later substance-related problems among teenagers [27].  
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 The present investigation addresses some of the limitations of earlier studies within this field. 
First of all, few studies have compared CPU and SPU [21, 25]. Second, studies have not 
thoroughly investigated the impact of the number of drugs simultaneously used, a variable that 
has already been suggested to reflect the level of severity of drug use in studies of CPU [15]. 
Notably, it has even been reported that the number of drugs used may be more important than the 
type of drugs used for the prediction of first suicide attempts [17]. However, there may be a 
methodological problem when studying SPU since it can be confounded with CPU (i.e., the more 
drugs people use simultaneously, the more drugs they must use concurrently). For this reason, 
some studies comparing SPU and CPU [21, 25] have not assessed the associations of SPU with 
variables while controlling for CPU. Another limitation of past studies is that they have focused 
on select substances, such as alcohol, tobacco, cannabis, and specific illicit drugs. Therefore, no 
previous study has investigated polydrug use patterns while considering a comprehensive list of 
drugs. 
 
The aims of this study were to examine the patterns of CPU and SPU in relation to a wide variety 
of drugs (18 drugs) and to determine the additional associations of SPU with health (i.e., relevant 
outcomes identified in previous studies on polydrug use: mental/physical health, social problems 
and consequences) following adjustment for CPU. Although this cross-sectional study did not 
allow us to define causality, regression models were used to test associations between health and 
SPU after adjusting for several factors, including CPU. 
 
2. Materials and methods 
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2.1 Subjects 
The data for this study were obtained from the Cohort Study on Substance Use Risk Factors (C-
SURF). C-SURF is an ongoing, longitudinal study designed to assess substance use patterns and 
related consequences in young Swiss men. Enrollment took place between August 23, 2010 and 
November 15, 2011 in three of the six army recruitment centers located in Lausanne (French-
speaking), and Windisch and Mels (German-speaking). These three centers cover 21 of 26 
cantons in Switzerland, including all French-speaking cantons. In Switzerland, army service is 
compulsory, so all young men ~20 years of age were eligible for inclusion in the study. Thus, our 
cohort is highly representative of young Swiss men. Moreover, this study was approved by the 
Ethics Committee for Clinical Research of the Lausanne University Medical School and 
followed the Helsinki declaration. 
 
Of the 13,245 conscripts informed about the study, 7,563 gave written consent to participate, and 
5,990 filled in the baseline questionnaire. This analysis was performed on baseline data only. 
The study focused on the 5,636 participants who had used at least one drug during the past 12 
months, including alcohol (94.1% of the sample). Subjects with missing values related to 
outcome variables were not considered in the analysis. Thus, the final study cohort included 
5,319 participants (94.4% of the sample). More information about sampling and non-response 
can be found in Studer et al. [28]. Early respondents (responses obtained without extra effort) 
were compared to late respondents (responses acquired through increased efforts [i.e., 
encouraging telephone calls]) and non-respondents (who answered a five-minute questionnaire 
on substance use during the enrollment phase of the C-SURF). Early respondents were less likely 
to be either substance users or heavy users in comparison to late respondents, and non-
Supprimé: e
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respondents showed generally higher patterns of substance use than late respondents (excluding 
alcohol use). Therefore, using late respondents greatly reduced the magnitude of the non-
response bias, even if it was insufficient to free survey estimates from the risk of non-response 
bias. However, differences between respondents and non-respondents were small and might be 
significant only because of the large sample size (N = 11,819). 
 
2.2 Measures 
2.2.1 CPU 
CPU. Concurrent polydrug use was assessed by asking participants whether they had used 
specific drugs during the past 12 months. Each drug was coded as “used” or “non-used”. The 
drugs included: 1) alcohol; 2) tobacco; 3) cannabis; 4) hallucinogens, magic mushrooms, 
psilocybin, peyote, or mescaline; 5) other hallucinogens (LSD, PCP/angeldust, 2-CB, or 2-CI); 
6) salvia divinorum; 7) speed; 8) amphetamine, methamphetamine, or amphetaminsulfate (e.g., 
Dexedrine, Benzedrine); 9) crystal meth (Ice); 10) poppers (amyl nitrite, butyl nitrite); 11) 
solvent sniffing (e.g., glue, solvent, or gas [benzin, ether, toulol, trichloroethylene, nitrous oxide, 
etc.]); 12) ecstasy, MDMA; 13) cocaine, crack, or freebase; 14) heroin; 15) ketamine (Special K) 
or DXM; 16) GHB/GBL/I-4 Butanediol (BDB); 17) research chemicals (e.g., mephedrone, 
butylone, or methedrone); and 18) spice or similar substances. 
Total CPU score. The global CPU score was determined by summing all of the drug categories 
used during the past 12 months (licit and illicit drugs combined, total score from 1 to 18, each 
positive category counted as “1” in the total score).  
 
2.2.2 SPU 
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SPU. The co-use of drugs was assessed by questioning participants about the drugs that they had 
combined during the past 12 months. Specifically, individuals were asked to divulge the usual 
number of drugs that they used on a usual occasion (“usual SPU”) and the maximum number of 
drugs that they had combined (“maximum SPU”). The drug categories used for this assessment 
were the same as those used for CPU scoring. 
Total SPU score. Two global SPU scores were determined (i.e., “usual SPU” and “maximum 
SPU”) by summing the total drugs used (licit and illicit drugs combined, total score from 0 to 18, 
each category counted as “1” for the total scores). 
 
2.2.3 Mental, social, and physical factors 
Anxiety and aggressiveness. In order to assess anxiety and aggressiveness, two subscales from 
the Zuckerman–Kuhlmann Personality Questionnaire (ZKPQ-50-cc) [29] were used: 
neuroticism/anxiety and aggression/hostility. The participants agreed or disagreed with each 
statement. A mean score was computed for each subscale (anxiety: α = .73; aggressiveness: α = 
.56). 
Depression. Depression level was determined by using the Major Depressive Inventory (MDI) 
from the International Statistical Classification of Diseases and Related Health Problems (ICD-
10) by the World Health Organization (WHO) [30, 31]. This is a 10-item questionnaire that 
screens answers on a 6-point scale from “never” (0) to “all the time” (5). A mean score was 
computed (α = 0.91). A continuous scale (ranging from 0 to 50) was used instead of a cutoff 
value in order to better capture variability across the range of depression symptoms. 
Mental and physical health. The Short Form Health Survey (SF-12) was used to assess mental 
and physical health [32] based on two subscales: mental/social health and physical health. The 
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subscale scores were computed according to the standard system, yielding two composite scores, 
which ranged from 0 (health problem) to 100 (no health problem). SF-12 primarily covered 
sadness, nervousness, and depression. 
Consequences. A total of 15 consequences were selected from standard instruments [33-36]. 
However, these items were not explicitly substance related, which has been shown to result in 
different associations compared to consequences that can be causally attributed to substances. 
Included items were related to social, personal, and health consequences. Each consequence was 
coded “0” if it had not occurred in the past 12 months and “1” if it had taken place at least once 
during the past 12 months. Two mean scores of consequences were computed. The first score 
was related to social consequences, which included physical fights, problems with family/ 
friends, poor performance at school/work, theft, trouble with the police, regretted sexual 
intercourse, or damage to property. The second score was related to health consequences, 
including accident/injury, admittance to an emergency department, attempted suicide, need for 
medical treatment, overnight stay in a hospital, outpatient surgery, and treatment of an 
accident/injury in an emergency department. 
 
2.3 Analyses 
To examine CPU and SPU patterns, descriptive cross tables were created for each kind of 
polydrug use (CPU, usual SPU, and maximum SPU). The association of SPU with health factors 
was subsequently tested using linear regression analyses. However, although linear regression 
analyses were performed, a causal relationship between SPU and health factors was not assessed. 
The aim of this study was to investigate their actual relationship. First of all, two models were 
created to test the association of SPU alone (usual SPU and maximum SPU) with the seven 
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factors considered as dependent variables (unadjusted models). We then took into account the 
effect of CPU (adjusted models). As SPU is part of CPU, we initially conducted linear regression 
analyses with CPU as the predictor and SPU (usual SPU and maximum SPU) as the dependent 
variable, recording the residual factors for each model. The residual factors were then used as 
independent variables when analyzing each of the seven health-related variables. This allowed us 
to extract the unique variance of SPU and to test the ‘pure’ association of SPU with health. 
Holm–Bonferroni correction [37] was used, and statistical significance was set at .05. All 
analyses were conducted using SPSS software (version 20). Also, standardized regression slopes 
(β) were presented instead of raw slopes to allow comparison between unadjusted and adjusted 
SPU with a scale free estimation [38]. 
 
3. Results 
3.1 Descriptive analysis 
Prevalence rates and descriptive statistics are shown in Tables 1 and 2. On average, the 
participants used 2.07 drugs for CPU (SD = 1.48), 1.46 drugs for usual SPU (SD = 1.03), and 
1.84 drugs for maximum SPU (SD = 1.27). The most commonly used drugs were: alcohol (the 
most widely used substance, with 97.8% of participants drinking at least once during the past 12 
months, 81.0% drinking at least once simultaneously on a usual occasion, and 84.6% drinking at 
least once simultaneously on occasions where they combined a maximum of various drugs), 
tobacco (49.8% CPU, 44.0–56.5% SPU), and cannabis (32.1% CPU, 15.4–29.2% SPU). Crystal 
meth, heroin, ketamine, GHB/GBL, research chemicals, and spice were the least commonly used 
drugs (0.3–0.5% CPU, 0.0–0.2% SPU).  
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[Please insert Tables 1 & 2 about here] 
 
3.2 CPU and SPU patterns 
Cross tables displaying the calculated CPU and maximum SPU values for each drug are 
presented. Cross tables are not presented for usual SPU because of the small sample size 
obtained for some drugs. Table 3 shows the results for CPU. Participants using only one drug, 
predominantly consumed alcohol (97.4%). When two drugs were used, it was most commonly 
alcohol (98.6%) and tobacco (78.3%). When three drugs were used, cannabis was added to 
alcohol and tobacco (94.3%). When 4–7 drugs were used as CPU, hallucinogens (magic 
mushrooms, others hallucinogens, salvia divinorum), uppers (ecstasy, cocaine, speed 
amphetamines/methamphetamines), and sniffed drugs (poppers and solvents) were incorporated. 
Finally, when eight or more drugs were used, spice, crystal meth, heroin, GHB/GBL, research 
chemicals, and ketamine were the choice substances to be added. Commonly, these ‘later stage’ 
drugs (i.e., spice, crystal meth, heroin, GHB/GBL, research chemicals, and ketamine) were 
added without replacing “early stage” drugs. 
 
[Please insert Table 3 about here] 
 
The results for maximum SPU were similar to CPU (Table 4). The first association was alcohol 
and tobacco (among the participants who reported the use of two drugs simultaneously, 98.7% 
used alcohol and 89.9% used tobacco), which were combined with cannabis when three drugs 
were used at the same time. When 4–5 drugs were used simultaneously, hallucinogens (magic 
mushrooms, others hallucinogens, salvia divinorum), uppers (ecstasy, cocaine, speed 
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amphetamines/methamphetamines), and sniffed drugs (poppers and solvents) were added to 
those drugs already being used. Spice, crystal meth, heroin, GHB/GBL, research chemicals, and 
ketamine were incorporated when six or more drugs were used. As with CPU, if additional drugs 
were simultaneously used, then participants commonly added them without replacing other drugs 
that were already in use. 
 
[Please insert Table 4 about here] 
 
3.3 Associations of SPU with mental, social, and physical factors 
The results for the models of usual and maximum SPU associations, with and without taking 
CPU into account, are shown in Table 5. In the unadjusted model, usual SPU was associated 
with all seven dependent variables, whereas maximum SPU was associated with six out of the 
seven dependent variables. When participants used more substances simultaneously, they also 
felt more depressed (β = .124–.136, p < .001), anxious (β = .053–.064, p < .001), and aggressive 
(β = .147–.182, p < .001). In addition, they had a poorer state of mental health (β = –.113 to –
.098, p < .001), and reported more negative social (β = .290–.304, p < .001) and health (β = .088–
.109, p < .001) consequences. There was also a negative association between physical health and 
usual SPU (β = –.052, p < .001). In the adjusted models, SPU also had an additive association 
with aggressiveness (β = .058–.115, p < .001) and negative social consequences (β = .098–.110, 
p < .001). However, SPU was no longer negatively associated with depression, anxiety, health 
consequences, or mental/physical health. The remaining associations were not as strong as those 
of the unadjusted models (e.g., aggressiveness: β = .147 for maximum SPU and β = .058 for 
residuals of maximum SPU). 
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 [Please insert Table 5 about here] 
 
4. Discussion 
4.1 Patterns of CPU and SPU 
This study investigated the patterns of CPU and SPU by examining separate cross tables for CPU 
and maximum SPU with each drug. The results indicated that drugs were commonly added for 
both CPU and maximum SPU. We found that when participants increased the number of drugs 
they using, they usually did not replace one drug with another. Instead, they added more drugs to 
those that were already in use. The order in which drugs were added resembled the sequential 
drug use patterns described in previous studies, with licit drugs (alcohol and tobacco) used 
initially, followed by cannabis and then other illicit drugs [39-42]. Apart from cannabis, the use 
of two distinct classes of illicit drugs was identified. The drugs that we found to be used first 
included: hallucinogens (magic mushrooms); other hallucinogens (LSD or salvia divinorum); 
uppers (speed, ecstasy, cocaine, amphetamines, or methamphetamines); and sniffed drugs 
(poppers or solvents). The use of these substances was followed by use of other ‘hard’ drugs, 
such as ketamine, heroin, GHB/GBL, research chemicals, crystal meth, and spice. In fact, it 
appeared that there was an escalation in the types of illicit drugs being used. In other words, the 
number of drugs used can be considered as an indicator of the severity of polydrug use. This 
result supports the use of “total number of drugs” as a relevant variable, as an increasing number 
of drugs added information (i.e., additional drugs to those already used), but was not something 
qualitatively different (e.g., other drugs instead of those already used). 
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4.2 Associations of SPU with mental, social, and physical factors 
Regression analyses showed that CPU was a confounding variable for SPU. When the models 
were not adjusted for CPU, SPU showed an association with all factors related to mental, social, 
and physical consequences (except physical health with SPU maximum). When the variance 
between CPU and SPU was taken into account, the only remaining associations were 
aggressiveness and negative social consequences (for both usual and maximum SPU). In other 
words, the number of drugs used concurrently had an important association with health factors, 
which is in line with previous studies [15-18]. It is well known that aggressiveness and social 
consequences are interrelated. Therefore, this finding might suggest that SPU will only display 
this independent association among a subgroup of individuals prone to these types of behavioral 
disorders. There was no significant association between SPU and depression, anxiety, or 
mental/physical health consequences when CPU was taken into account. These results were 
interesting as they may indicate that users understood the pharmacology of the drugs they used, 
combining them intentionally to reduce undesired effects [20, 43, 44]. Indeed, some associations 
are well known (e.g., alcohol reduces the discomfort of coming down from cocaine [26, 45], and 
cocaine attenuates the negative effects of alcohol) [26]. In addition, heroin can be used when 
coming down from cocaine to attenuate its anxiogenic effects, whereas cocaine can be used to 
temper the depressive effects of heroin [46]. Thus, the absence of association between SPU and 
depression, anxiety, or mental health may be explained by a users’ intention to combine drugs in 
order to avoid particular detrimental effects, such as depression and anxiety. Another explanation 
could be that the number of drugs used accounts for associations with health/consequences and 
that combined simultaneous use does not add more to this association. This would mean that 
measuring the solely number of drugs used, and not necessarily their simultaneous use, may be 
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sufficient in substance use surveys. Further investigations will be needed to test these two 
hypotheses. 
 
4.3 Limitations 
The main limitation of this study was its cross-sectional design. This design did not allow a 
conclusion to be made on whether polydrug use was a cause or a consequence of health, mental, 
and social problems, as is often the case in these types of studies [47, 48]. However, C-SURF is a 
longitudinal study, and future analyses will focus on studying the effect of past drug use on 
current psychological distress. Another limitation of our study was that it did not include female 
participants. Associations between polydrug use and health factors should be studied in a sample 
of women in order to assess the potential differences between men and women with regard to 
these findings. A third limitation involved the use of a personality scale to assess anxiety and 
aggressiveness. Although this scale can be employed to examine the level of anxiety or 
aggressiveness at a given time point, further studies using questions more closely related to 
psychological health or distress are needed. 
 
5. Conclusion 
Here, we have demonstrated that the pattern of CPU and SPU within a sample of young adult 
men followed previously described stages of drug use, involving the sequential use of alcohol, 
tobacco, cannabis, and then other illicit drugs. In addition, two distinct classes of illicit drugs 
were identified. The first class included uppers, hallucinogens, and sniffed drugs, whereas the 
second class included ketamine, heroin, GHB/GBL, research chemicals, crystal meth, and spice. 
As the users progressed along this sequence of drug use, they did not stop taking any of the drugs 
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that they were already using. For this reason, the number of drugs used can be seen as a proxy of 
the severity of polydrug use. 
 
The additive effect of SPU on CPU was also assessed in this study. Previous reports have 
indicated that SPU can be distinguished from CPU. Thus, even though these two concepts are 
linked, they remain discriminable constructs [19]. Consistent with this idea, we have found that 
SPU is independently associated with social factors, including aggressiveness and negative social 
consequences among young men. However, we did not observe any relevant associations with 
some specific outcomes related to mental health, such as depression or anxiety. 
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  % of users 
  CPU Usual SPU Maximum SPU 
Alcohol 97.8 81.0 84.6 
Tobacco 49.8 44.0 56.5 
Cannabis 32.1 15.4 29.2 
Hallucinogens/magic mushrooms 2.7 0.3 1.1 
Other hallucinogens 2.3 0.5 1.3 
Salvia divinorum 2.1 0.2 0.8 
Speed 2.7 0.7 1.6 
Amphetamine/methamphetamines 1.9 0.5 0.9 
Crystal meth 0.3 0.1 0.1 
Poppers 2.6 0.3 0.8 
Inhalants 2.2 0.2 0.6 
Ecstasy 3.8 1.1 2.6 
Cocaine 3.3 0.9 2.4 
Heroin 0.3 0.1 0.1 
Ketamine 0.5 0.0 0.2 
GHB/GBL 0.4 0.1 0.2 
Research chemicals 0.3 0.0 0.1 
Spice 0.5 0.0 0.1 
    Table 1. Prevalence rates for each drug for CPU, usual SPU, and maximum SPU 
For example, 97.8% of the participants used alcohol concurrently during the past 12 months, whereas only 0.5% 
used spice concurrently during the past 12 months. On a usual occasion, 81.0% of the participants drank alcohol 
simultaneously with another substance, and only 0.1% of them used heroin simultaneously with another substance. 
  
Mean SD 
CPU (1-18) 2.07 1.48 
SPU usual (0-18) 1.46 1.03 
SPU maximum (0-18) 1.84 1.27 
Social consequences (0-1) 0.22 0.21 
Health consequences (0-1) 0.17 0.19 
Depression (0-5) 0.69 0.70 
Aggressiveness (0-1) 0.42 0.21 
Anxiety (0-1) 0.20 0.20 
Mental health (0-100)1 47.36 9.01 
Physical health (0-100)1 53.11 6.26 
Table 2. Descriptive statistics for polydrug use and outcomes 
Remarks: Ranges are given in brackets. SD: standard deviation. 
1 A higher score indicated better health, in contrast to the other variables in the table. The value 50 is the 
standardized mean. 
   CPU – number of drugs used   
  
1 
N= 
2341 
2 
N= 
1459 
3 
N= 
1077 
4 
N= 
199 
5 
N= 
72 
6 
N= 
58 
7 
N= 
39 
8 
N= 
22 
9 and more 
N= 
52 
Alcohol 97.4 98.6 99.9 98.5 100 100 100 100 94.2 
Tobacco 2.2 78.3 96.5 98.0 97.2 96.6 97.4 100 90.4 
Cannabis 0.3 19.5 94.3 91.5 98.6 94.8 92.3 100 86.5 
Poppers 0.0 1.3 1.8 19.6 20.8 22.4 17.9 13.6 42.3 
Hallucinogens/magic mushrooms 0.0 0.3 0.8 17.1 23.6 34.5 43.6 40.9 69.2 
Salvia divinorum 0.0 0.2 0.5 17.1 19.4 13.8 30.8 31.8 61.5 
Ecstasy 0.0 0.1 0.9 14.1 33.3 63.8 74.4 100 96.2 
Cocaine 0.0 0.1 1.1 12.1 33.3 55.2 59.0 59.1 90.4 
Solvent sniffing 0.0 1.4 2.4 11.6 20.8 17.2 12.8 9.1 28.8 
Speed 0.0 0.0 0.8 6.5 16.7 36.2 61.5 68.2 94.2 
Other hallucinogens 0.0 0.1 0.3 3.5 15.3 37.9 46.2 77.3 82.7 
Amphetamine/methamphetamines 0.0 0.0 0.2 5.5 13.9 13.8 41.0 54.5 84.6 
Spice 0.0 0.1 0.1 1.5 2.8 6.9 7.7 4.5 19.2 
Chrystal meth 0.0 0.1 0.1 0.0 1.4 0.0 2.6 13.6 19.2 
Heroin 0.0 0.0 0.0 0.5 1.4 0.0 0.0 4.5 25.0 
GHB/GBL 0.0 0.0 0.2 1.0 0.0 1.7 0.0 13.6 28.8 
Research chemicals 0.0 0.0 0.1 1.0 0.0 3.4 5.1 4.5 19.2 
Ketamine 0.0 0.0 0.0 1.0 1.4 1.7 7.7 4.5 34.6 
Table 3. Percentages of each drug use according to the number of CPU 
For example, among the participants who used 1 drug concurrently (n= 2,341), 97.4% drink alcohol, 2.2% smoke 
tobacco, 0.3% use cannabis, and 0.1% use solvent 
   Maximum SPU – number of drugs used 
  
2 
N= 
1734 
3 
N= 
1159 
4 
N= 
153 
5 
N= 
47 
6 
N= 
40 
7 and more 
N= 
36 
Alcohol 98.7 99.1 98.7 97.9 97.5 94.4 
Tobacco 89.9 98.4 98.0 95.7 97.5 94.4 
Cannabis 10.5 95.7 90.8 100 97.5 100 
Ecstasy 0.1 1.3 22.2 53.2 75.0 94.4 
Cocaine 0.2 1.4 19.6 53.2 60.0 77.8 
Hallucinogens/magic mushrooms 0.1 0.5 14.4 10.6 17.5 44.4 
Others hallucinogens 0.1 0.5 12.4 14.9 27.5 61.1 
Salvia divinorum 0.0 0.3 13.1 12.8 10.0 25.0 
Poppers 0.2 0.7 12.4 10.6 10.0 13.9 
Speed 0.1 0.7 5.9 25.5 67.5 72.2 
Solvent sniffing 0.1 1.1 5.2 4.3 7.5 13.9 
Amphetamine/methamphetamines 0.1 0.1 2.6 14.9 22.5 69.4 
GHB/GBL 0.0 0.0 0.7 0.0 5.0 22.2 
Research chemicals 0.0 0.1 1.3 0.0 2.5 8.3 
Ketamine 0.0 0.1 2.0 2.1 2.5 13.9 
Spice 0.1 0.1 0.7 2.1 0.0 11.1 
Crystal meth 0.1 0.0 0.0 0.0 0.0 5.6 
Heroin 0.0 0.0 0.0 2.1 0.0 16.7 
Table 4. Column percentages of each drug use according to the number of maximum SPU drug 
use 
For example, among the participants who used 2 drugs simultaneously (n= 1,734), 98.7% drink alcohol, 89.9% 
smoke tobacco, 10.5% use cannabis, 0.2% use cocaine, 0.2% use poppers, and 0.1% use ecstasy, hallucinogens such 
as magic mushrooms, others hallucinogens, speed, solvent, amphetamines/methamphetamines, spice and crystal 
meth. 
  SPU (unadjusted)   Residuals from CPU models (adjusted) 
 
usual maximum 
 
usual maximum 
Outcomes β (SE) β (SE) 
 
β (SE) β (SE) 
Social consequences .290 (0.003)*** .304 (0.002)*** 
 
.110 (0.004)*** .098 (0.003)*** 
Health consequences .088 (0.014)*** .109 (0.14)*** 
 
.011 (0.013) .025 (0.014) 
Aggressiveness .182 (0.014)*** .147 (0.014)*** 
 
.115 (0.014)*** .058 (0.014)*** 
Anxiety .064 (0.014)*** .053 (0.014)*** 
 
.021 (0.014) -.004 (0.013) 
Physical health -.052 (0.014)*** -.034 (0.014) 
 
-.020 (0.014) .012 (0.013) 
Mental health -.098 (0.014)*** -.113 (0.014)*** 
 
-.011 (0.014) -.013 (0.014) 
Depression .124 (0.014)*** .136 (0.014)***  .021 (0.014) .014 (0.013) 
Table 5. Standardized slopes (β) of regression analyses for unadjusted and adjusted models of 
health issues on SPU. 
Remarks: Standardized standard errors (SE) are given in parentheses. 
rCPU, usual SPU = 0.645***; rCPU, maximum SPU =0.748*** 
* p < .05, ** p < .01, *** p < .001. p-values with a Holm–Bonferroni correction are given.  
 
 
